Actively Recruiting
A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults
Led by Syntis Bio · Updated on 2026-04-29
64
Participants Needed
1
Research Sites
50 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacodynamics of single and multiple dose regimens of SYNT-101 in healthy and overweight adults.
CONDITIONS
Official Title
A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to understand the study purpose and risks
- Adults aged 18 to 55 years at screening
- Medically healthy without significant abnormalities
- Have suitable venous access for blood sampling
- Willing and able to follow study assessments and schedule
You will not qualify if you...
- Known allergy to SYNT-101 or its ingredients
- History of anaphylaxis or significant allergy affecting participation
- History or presence of significant cardiovascular, lung, liver, kidney, blood, hormonal, immune, skin, psychiatric, or neurological diseases or disorders
- Any acute illness within the past 3 months deemed relevant by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Veritus Research
Bayswater, Victoria, Australia
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here